在亚托匹性皮肤炎的创新和新兴疗法 第2部分
1Department of Dermatology, Oregon Health and Sciences University, 3303 S Bond Ave Building 1, 16th Floor, Portland, OR 97239, USA.
Current treatment options in allergy
|July 9, 2025
概括
新型局部疗法为亚托皮炎 (AD) 治疗提供了更好的疗效和安全性,解决了旧药物的缺点. 未来的研究应该扩展长期数据,以优化局部AD管理.
科学领域:
- 皮肤病学 皮肤病学
- 药理学 药理学 是一个学科.
- 免疫学 免疫学 免疫学
背景情况:
- 亚托匹性皮肤炎 (AD) 管理已经取得了重大进展.
- 针对阿尔茨海默病的全身疗法已经发展,现在的重点转向局部治疗.
- 针对阿尔茨海默病的传统局部治疗有局限性,而新的治疗方法旨在克服这些局限性.
研究的目的:
- 审查针对阿托皮性皮炎 (AD) 的局部治疗方法的新方面.
- 为了比较和讨论当前针对AD的局部治疗研究中的缺陷.
- 在对全身疗法的审查后,介绍阿尔茨海默病局部疗法的进展.
主要方法:
- 文献综述,重点关注当前阿尔茨海默病治疗的最新进展.
- 对比新型和传统局部治疗方法的研究分析.
- 对局部AD治疗的现实世界和长期数据的评估.
主要成果:
- 最近对AD的局部治疗选择的演变.
- 新型,分子向的局部疗法的出现.
- 这些向疗法显示出克服传统局部药物的缺点的潜力.
结论:
- 转向针对性局部AD疗法的转变与提高疗效和安全性有关.
- 改善患者服从是较新的局部治疗方法的一个明显好处.
- 未来的研究需要扩展长期数据,以优化局部AD治疗.
相关概念视频
Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
471
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
471
Clinical Applications of Epidermal Stem Cells
2.8K
Epidermal stem cells (EpiSCs) are mainly located at the basal layer of the epidermis. These cells repair minor injuries of the skin and replace dead skin cells. However, EpiSCs’ cannot heal severe wounds such as major burns or those from diabetes or hereditary disorders. In such cases, culturing the epidermal stem cells from the patient is possible and has yielded successful treatment options, such as laboratory-grown skin grafts. These grafts are synthesized using a patient’s own...
2.8K
Inflammatory Bowel Disease IV: Pharmacological Management
200
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
200
Asthma: Pathogenesis and Management
607
Asthma is a chronic pulmonary condition involving inflammation of the airways, hyper-reactivity, and reversible obstruction of the airways. This condition can significantly impact a person's quality of life, making breathing difficult and leading to distressing symptoms.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
607
Tumor Immunotherapy
665
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
665
Antiasthma Drugs: Leukotriene Modifiers
489
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Leukotriene modifiers work through two distinct mechanisms:
489


